BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33591648)

  • 1. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).
    Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J
    Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.
    Ge L; Lu S; Xu L; Yan H
    Clin Neurol Neurosurg; 2021 Sep; 208():106838. PubMed ID: 34339901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
    Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
    Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
    Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
    Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
    Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
    APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].
    Chen XL; Li XY; Wang W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1410-1414. PubMed ID: 29070116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
    Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
    Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
    Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
    J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.